These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs. Non-Users. Lee HF, Chan YH, Hsu TJ, Chuang C, Li PR, Yeh YH, Su HC, Hsiao FC, See LC. Clin Pharmacol Ther; 2024 Aug; 116(2):426-434. PubMed ID: 38738997 [Abstract] [Full Text] [Related]
3. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC. Cardiovasc Diabetol; 2020 Sep 30; 19(1):160. PubMed ID: 32998736 [Abstract] [Full Text] [Related]
4. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q. Cardiovasc Drugs Ther; 2023 Jun 30; 37(3):561-569. PubMed ID: 35142921 [Abstract] [Full Text] [Related]
5. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Circulation; 2018 Apr 03; 137(14):1450-1459. PubMed ID: 29133607 [Abstract] [Full Text] [Related]
8. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study. Jang J, Park S, Kim S, Kim SH, Oh YS, Sa YK, Hwang Y, Jang SW, Ihm SH, Choi Y. Eur J Prev Cardiol; 2024 Feb 15; 31(3):320-329. PubMed ID: 37798123 [Abstract] [Full Text] [Related]
9. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. Zhou J, Lee S, Leung KSK, Wai AKC, Liu T, Liu Y, Chang D, Wong WT, Wong ICK, Cheung BMY, Zhang Q, Tse G. ESC Heart Fail; 2022 Apr 15; 9(2):1388-1399. PubMed ID: 35132823 [Abstract] [Full Text] [Related]
10. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH. Cardiovasc Diabetol; 2020 Nov 06; 19(1):188. PubMed ID: 33158436 [Abstract] [Full Text] [Related]
12. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation. Chen YY, Chang HC, Lin YJ, Chien KL, Hsieh YC, Chung FP, Lin CH, Lip GYH, Chen SA. Diabetes Metab Res Rev; 2024 Feb 06; 40(2):e3775. PubMed ID: 38340046 [Abstract] [Full Text] [Related]
16. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC, Lip GYH. Cardiovasc Diabetol; 2022 Jun 28; 21(1):118. PubMed ID: 35765074 [Abstract] [Full Text] [Related]
20. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin. McCormick N, Yokose C, Lu N, Wexler DJ, Aviña-Zubieta JA, De Vera MA, McCoy RG, Choi HK. JAMA Intern Med; 2024 Jun 01; 184(6):650-660. PubMed ID: 38619822 [Abstract] [Full Text] [Related] Page: [Next] [New Search]